期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 82, 期 5, 页码 601-605出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.clpt.6100361
关键词
-
资金
- NCRR NIH HHS [K12RR023266] Funding Source: Medline
- NIGMS NIH HHS [T32GM066691] Funding Source: Medline
Combination drug therapy for malaria is recommended both to prevent and to overcome drug resistance. Drug combinations developed for use in Asia are being deployed in Africa, where higher rates of malaria affect the therapeutic and public health objectives of malaria chemotherapy as well as drug safety. Rational consideration of drug mechanisms, pharmacokinetics (PK), pharmacodynamics (PD), and malaria epidemiology should result in more effective combination regimens that retain therapeutic and prophylactic efficacy in the face of resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据